MRC1 and malignant colon neoplasm: A recent study conducted in patients with stage II colon cancer showed that patients with a high M2/M1 (CD206+/CD68+) macrophage ratio were more likely to benefit from adjuvant chemotherapy than patients with a low M2/M1 ratio, who did not show any clinical benefit—therefore, identifying a subset of patients that would not need additional treatment following surgery [49].